---
document_datetime: 2024-04-18 12:21:41
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/javlor-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: javlor-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.843431
conversion_datetime: 2025-12-20 17:42:26.208919
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Javlor

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0025/G            | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 16/04/2024                          |                                             | SmPC, Annex II and PL            |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | C.I.11.z - Introduction of, or change(s) to, the                                                                                                                                                                                                         |            |            |                                  |                     |               |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------|---------------|
| PSUSA/3123/ 202109 | Periodic Safety Update EU Single assessment - vinflunine                                                                                                                                                                                                 | 05/05/2022 | n/a        |                                  | PRAC Recommendation | - maintenance |
| IAIN/0023/G        | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 02/02/2022 | 23/05/2023 | SmPC, Annex II, Labelling and PL |                     |               |
| IAIN/0021          | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                               | 07/01/2021 | 24/01/2022 | Annex II and PL                  |                     |               |
| PSUSA/3123/ 201809 | Periodic Safety Update EU Single assessment - vinflunine                                                                                                                                                                                                 | 16/05/2019 | n/a        |                                  | PRAC Recommendation | - maintenance |
| N/0019             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                         | 19/02/2018 | 24/01/2022 | Labelling                        |                     |               |
| PSUSA/3123/ 201609 | Periodic Safety Update EU Single assessment - vinflunine                                                                                                                                                                                                 | 06/04/2017 | n/a        |                                  | PRAC Recommendation | - maintenance |
| PSUSA/3123/ 201509 | Periodic Safety Update EU Single assessment - vinflunine                                                                                                                                                                                                 | 14/04/2016 | n/a        |                                  | PRAC Recommendation | - maintenance |

<div style=\"page-break-after: always\"></div>

| PSUSA/3123/      | -                                                                             |                       |                |             |                                                                                           |
|------------------|-------------------------------------------------------------------------------|-----------------------|----------------|-------------|-------------------------------------------------------------------------------------------|
| 201409 PSUV/0015 | Periodic Safety Update EU Single assessment vinflunine Periodic Safety Update | 10/04/2015 25/04/2014 | n/a 19/06/2014 | SmPC and PL | PRAC Recommendation - maintenance The MAH proposed to add a warning to section 4.4 of the |
| R/0014           | Renewal of the marketing authorisation.                                       | 20/03/2014            | 16/05/2014     | SmPC, Annex |                                                                                           |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            | and PL                    |                                                                                                                                                                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0013/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.c.2.z - Change in the specification parameters and/or limits of the immediate packaging of the AS - | 14/01/2014 | n/a        |                           |                                                                                                                                                                        |
| N/0012    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 08/11/2013 | 16/05/2014 | PL                        |                                                                                                                                                                        |
| IAIN/0010 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 08/02/2013 | n/a        |                           |                                                                                                                                                                        |
| II/0007/G | This was an application for a group of variations. This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/05/2012 | 27/06/2012 | SmPC, Annex II, Labelling | The MAH identified a total of four cases of PRES following vinflunine use over the period December 1998 to May 2011. These included one clinical trial and three post- |

<div style=\"page-break-after: always\"></div>

|         | Update of sections 4.4 'Special warnings and precautions for use' and 4.8 'Undesirable effects' of the Summary of Product Characteristics (SmPC) to include information on \"Posterior Reversible Encephalopathy Sydrome\" (PRES) and 'Tumor Pain' as adverse reactions. Section 2 of the Package Leaflet (PL) has been updated accordingly. Further editorial changes were made to sections 4.2 and 4.6 of the SmPC, and the Package Leaflet. In addition, the MAH also took the opportunity to include minor editorial changes to adapt the Product Information to the new QRD template (v8.1). C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46,   |            |            | and PL   | marketing reports. Therefore, as a risk minimisation measure, the MAH included a recommendation for blood pressure control and reference to brain imaging to confirm a diagnosis of PRES in section 4.4 of the SmPC. The frequency for PRES ('rare') was calculated based on a non- TCCU clinical trial report and was included in section 4.8 of the SmPC. A total of three cases of tumour pain following Javlor use were also reported post marketing. An association of the adverse reaction with the drug was plausible in these cases. The frequency of this adverse reaction could not be estimated from post-marketing data, hence 'frequency not known' was included in section 4.8 of the SmPC.   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0008 | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 26/06/2012 | 29/10/2012 | SmPC     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| IAIN/0009/G   | This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of                                                                                                                                                                   | 12/06/2012   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0006       | Update of sections 4.2 \"Posology and Method of Administration\" and 5.2 \"Pharmacokinetic properties\" of the Summary of Product Characteristics (SmPC) in order to include the results and conclusions of Study L00070 IN 113, as requested in FUM 2. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 22/09/2011   | 10/11/2011 | SmPC                  | Following the assessment of FUM2, the MAH has updated the following sections of the SmPC; section 4.2 to note that in renally impaired patients, further cycles should be adjusted in the event of toxicities, and that the recommended dose after Cycle 1 in such cases should be the same as that specified for elderly patients; section 5.2 to provide a brief descriptive update regarding study L00070 IN 113, concluding that Vinflunine clearance is reduced when creatinine clearance is decreased. |
| II/0004/G     | This was an application for a group of variations. Update of sections 4.2, 4.3, 4.4, 4.5 and 4.8 of the Summary of Product Characteristics (SmPC) following the assessment of PSUR 1. The Marketing Authorisation Holder (MAH) has also taken the opportunity to update sections 4.6, 4.7, 5.1, 6.2 and 10 of the SmPC and Annex II B with                                                                                                                                                                      | 22/09/2011   | 10/11/2011 | SmPC, Annex II and PL | Following the assessment of PSUR1, the MAH has updated the following sections of the SmPC; section 4.2 to provide further information on adequate monitoring of platelets and haemoglobin, dose delays or discontinuation due to toxicity in patients with neutropenia, thrombocytopenia, organ toxicity or cardiac ischaemia, additional precision in the grading of toxicities such as mucositis, constipation, nausea, and vomiting, and recommendations on dose                                          |

<div style=\"page-break-after: always\"></div>

|           | minor editorial changes. Sections 2, 3 and 4 of the Package leaflet have been updated accordingly. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with   |            |     | adjustments for patients with hepatic impairment and the elderly; section 4.3 to clarify the contraindications with regards to neutrophil and platelet count; section 4.4 to include leucopenia, anaemia and thrombocytopenia as adverse reactions, a cross reference to section 4.3 with regards to the contraindication on baseline neutrophil and platelet count, deletion of \"cumulative constipation\", replacement of \"heavy abdominal surgery\" by \"major abdominal surgery\", replacement of \"polyethylene glycol\" with \"an osmotic laxative\", additional precisions on the use of laxatives and further information on the grading of gastrointestinal toxicity; section 4.5 with further information on the potential for interaction between vinflunine and doxorubicin; section 4.8 to add rash, urticaria and erythema and skin and subcutaneous tissue disorders. Sections 4.6, 4.7, 5.1, 6.2,10 of the SmPC and Annex II B have been updated with minor editorial comments and section 2, 3 and 4 of the Package Leaflet (PL) have been aligned with the SmPC.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0005/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 23/06/2011 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002 | Update of section 4.8 \"Undesirable effects\" of the Summary of Product Characteristics (SmPC) to amend the frequencies of adverse events, which are inaccurate. The Marketing Authorisation Holder (MAH) has also taken the opportunity to update Section 4.2, 4.4, 4.5, 4.6, 5.2, 5.3, 6.2, 6.3 and 6.6 of the SmPC with minor editorial/linguistic changes, and the relevant section in the Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 18/11/2010 | 20/12/2010 | SmPC and PL           | The MAH has amended the frequencies of adverse events in section 4.8 \"Undesirable effects\" of the SmPC, arguing that the methodology initially used to calculate the worst grade by patient of each grouping term was incorrect. This calculation was inaccurate due to the fact that the patients who experienced several individual MedDRA preferred terms of the same group were counted several times within this group. The adverse events affected by these changes are infections (viral, bacterial, fungal), visual disturbances, sensory peripheral neuropathy, common cough, dyspnoea, abdominal pain, constipation, ileus, buccal disorders, cutaneous reactions, pruritus, arthralgia, ashtenia/fatigue, injection site reactions, chest pain, transaminase increase, neutropenia, severe anaemia, thrombocytopenia, and febrile neutropenia. At the same time, the MAH has made minor editorial/linguistic changes to Section 4.2, 4.4, 4.5, 4.6, 5.2, 5.3, 6.2, 6.3 and 6.6 of the SmPC and the PL. |
| II/0001 | Update of sections 4.2, 4.4 and 5.2 of the Summary of Product Characteristics (SmPC) with dose adjustments for the elderly population following the submission of the final study report of L00070IN 114 \"Pharmacokinetic Study of IV Vinflunine in Elderly Cancer Patients\" to fullfull FUM 003. The Marketing Authorisation Holder (MAH) has also taken the opportunity to update Section 3 of the Package leaflet accordingly. Annex II B has been updated in line with the EC                                                                                    | 18/11/2010 | 20/12/2010 | SmPC, Annex II and PL | Further to the request of the CHMP to fulfill FUM 003, the MAH has included dose adjustments in sections 4.2 \"Posology and Method of Administration, 4.4 \"Special Warnings and Precautions for Use\", and 5.2 Pharmacokinetic Properties of the SmPC, in elderly patients aged 75 years or more. The MAH has also updated section 3 of the PL to align it with the SmPC, reflecting the need to adjust the dose of vinflunine based on the age, physical conditions, and specific situation of the patient.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | decision to delete the version number of the DDPS. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0003 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                      | 30/07/2010 | n/a |